Abstract 422P
Background
Metastatic osteosarcoma at presentation forms 10 to 20% of total osteosarcomas diagnosed. They have a very poor prognosis compared to non-metastatic subset. Patients with resectable metastasis have a better DFS and OS compared to unresectable metastatic disease at presentation. This study was done to find the response rate to first line cisplatin and adriamycin combination chemotherapy to upfront metastatic osteosarcoma patients and time to progression after first line chemotherapy. Secondary objective was to find the overall survival.
Methods
Patients diagnosed with osteosarcoma at madras medical college were identified from the database for a period of 5.5 years from January 2013 to June 2018. From that patients who had metastasis at presentation were further sorted out and taken for analysis.
Results
77 patients were diagnosed to have osteosarcoma during the 5.5year period. Among them 36 patients had metastatic disease at presentation. 28 patients were male (77.8%) and 8 patients were female (22.2%). Median age of the patients was 19.5 years. 23 patients had ECOG PS 2 (63.9%) and 12 had ECOG PS 1 (33.3%) and 1 had ECOG PS 3 (2.8%). Tibia and femur were the most common primary site (75%). 5 patients had resectable lung metastasis and underwent pulmonary metastasectomy and were excluded from analysis and 1 patient was on palliative care only. Among remaining 30 patients, 27 patients had multiple lung metastasis (90%) and 3 patients had bone metastasis (10%). 30 patients received 6 cycles of chemotherapy with adriamycin 25mg/m2 on d1-d3 and cisplatin 100mg/m2 on d1 repeated every 21 days except 3 who progressed during chemotherapy. 17 patients (56.7%) had grade 1-2 vomiting. No one developed any acute cardiotoxicity. No treatment related death occurred. At the end of 6 cycles, 22 patients (73.3%) had partial response and 5 patients (16.7%) had stable disease and 3 patients (10%) had progressive disease. Median time to progression was 11.5 months. 2year OS was 73.3%.
Conclusions
This platinum doublet is a reasonable option for these patients as most of them are young.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sivasubramaniam Kumaravelu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
253P - Non-Epithelial Tumours of Ovary, An Experience from Qatar
Presenter: Ammar Madani
Session: e-Poster Display Session
260P - A phase I study of copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, in Chinese patients with relapsed indolent non-Hodgkin lymphoma (iNHL)
Presenter: Yuqin Song
Session: e-Poster Display Session
261P - Clinical outcomes of early-progressed follicular lymphoma in Korea: A multicenter, retrospective analysis
Presenter: Jun Ho Yi
Session: e-Poster Display Session
262P - Correlation between phosphorylated pI3K expression, phosphorylated AKT, and phosphorylated MTOR with serum dehydrogenase lactate level in non-Hodgkin lymphoma
Presenter: Hary Gustian
Session: e-Poster Display Session
263P - Good response to chemotherapy in primary CNS lymphoma may not translate into significant neurocognitive improvement in comatose patients
Presenter: Ryan Lim
Session: e-Poster Display Session
264P - Treatment outcome of primary testicular lymphoma patients treated in tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
271P - Cost-effectiveness of pembrolizumab as monotherapy or in combination with chemotherapy versus EXTREME regimen for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Taiwan
Presenter: Cheng Hsu Wang
Session: e-Poster Display Session
272P - Early metabolic changes in PET metrics over initial 8 weeks of treatment in patients with advanced head neck squamous cell carcinomas treated with chemotherapy
Presenter: Ashish Vaidya
Session: e-Poster Display Session
273P - Long term outcomes of locally advanced & borderline resectable esthesioneuroblastoma and sinonasal tumour with neuroendocrine differentiation treated with neoadjuvant chemotherapy
Presenter: Vikas Talreja
Session: e-Poster Display Session
274P - Comparing comorbidity indices in predicting 90-day mortality after radical radiotherapy for head and neck cancer
Presenter: Therese Tsui
Session: e-Poster Display Session